This study is looking for Veterans with central sleep apnea (CSA) to understand how different treatments work. CSA is a breathing problem during sleep, often seen in people with heart failure or those using opioid pain medicines. Current treatments like CPAP (continuous positive airway pressure) don't always work well enough. This study will test combination therapies, meaning you would receive PAP therapy along with one of three medications: Acetazolamide, Zolpidem, or Buspirone. Researchers want to see how these combinations affect your central apnea index (how often you stop breathing) and your CO2 reserve (a measure of your breathing control) over 120 days. The goal is to find better ways to treat CSA by targeting different parts of how your body controls breathing. All research activities are currently on hold due to COVID-19.

Study design

This is an interventional study planning to enroll 200 participants. It will compare different drug combinations with PAP therapy.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your CO2 reserve and central apnea indices will be measured at 120 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.